Developing scalable and modular technologies for continuous biopharmaceutical production
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Chemical Engineering, 2018
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Thesis |
| Language: | eng |
| Published: |
Massachusetts Institute of Technology
2019
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/1721.1/121817 |
| _version_ | 1826197450599170048 |
|---|---|
| author | Mozdzierz, Nicholas J.(Nicholas Joseph) |
| author2 | Richard D. Braatz and J. Christopher Love. |
| author_facet | Richard D. Braatz and J. Christopher Love. Mozdzierz, Nicholas J.(Nicholas Joseph) |
| author_sort | Mozdzierz, Nicholas J.(Nicholas Joseph) |
| collection | MIT |
| description | Thesis: Ph. D., Massachusetts Institute of Technology, Department of Chemical Engineering, 2018 |
| first_indexed | 2024-09-23T10:48:10Z |
| format | Thesis |
| id | mit-1721.1/121817 |
| institution | Massachusetts Institute of Technology |
| language | eng |
| last_indexed | 2024-09-23T10:48:10Z |
| publishDate | 2019 |
| publisher | Massachusetts Institute of Technology |
| record_format | dspace |
| spelling | mit-1721.1/1218172019-12-06T03:55:24Z Developing scalable and modular technologies for continuous biopharmaceutical production Mozdzierz, Nicholas J.(Nicholas Joseph) Richard D. Braatz and J. Christopher Love. Massachusetts Institute of Technology. Department of Chemical Engineering. Massachusetts Institute of Technology. Department of Chemical Engineering Chemical Engineering. Thesis: Ph. D., Massachusetts Institute of Technology, Department of Chemical Engineering, 2018 Cataloged from PDF version of thesis. Includes bibliographical references (pages 327-353). The existing biopharmaceutical manufacturing paradigm is poorly suited to produce biologic drugs on demand at a point-of-care. Generally, commercial-scale manufacturing using fed-batch cultivation and fixed infrastructure is concentrated in developed nations and results in process cycle times of weeks or months. Coupled with the complex logistical challenges associated with continuous 'plant-to-patient' cold-chains, the geographically biased nature of therapeutic protein production today can limit access to biologic drugs in developing areas of the world. These same logistical hurdles can also hamper the efficient distribution of life-saving protein therapeutics following crises in developed nations. Compounding these issues is the fact that lead times between bioreactor inoculation and patient dosing typically range from 6 to 12 months due to processing and regulatory constraints. As such, there is an opportunity to create technologies capable of rapidly generating biopharmaceuticals in emergency situations and remote healthcare settings. A platform that couples modular flow-through bioreactors and purification systems with real-time feedback control has the potential to bridge this gap if developed in parallel with appropriate expression hosts. To this end, we first developed a state-of-the-art microfluidic perfusion process that supported sustained secretion of heterologous proteins from the yeast Komagataella phaffi. Using palm-sized bioreactors with a 1 mL cultivation volume, we showed that 1 - 10 adult doses worth of hGH or IFN[alpha]-2b could be manufactured in under 24 hours. Next, we reengineered an array of 1 L-scale stirred-tank bioreactors to operate under continuous perfusion conditions and integrate with custom-built reconfigurable chromatography systems. Leveraging controllers designed in-house, we demonstrated that this system was capable of meeting the metabolic demands of high-density cultures of K. phaffi and preventing perfusion filter fouling. We further showed the production of high-quality hGH and IFN[alpha]-2b via the direct transfer of cell-free perfused supernatant onto a chromatography system, and extended these results to the automated expression and purification of over 400 adult doses of hGH in under one week. Finally, we designed and built a scalable, tubular crystallizer that leverages continuous slug-flow, directed ultrasonic irradiation, modular counter-current heat exchangers, and model-predictive control to tune the crystal size distributions of small-molecules and proteins alike. by Nicholas J. Mozdzierz. Ph. D. Ph.D. Massachusetts Institute of Technology, Department of Chemical Engineering 2019-07-18T20:32:38Z 2019-07-18T20:32:38Z 2018 2018 Thesis https://hdl.handle.net/1721.1/121817 1103713261 eng MIT theses are protected by copyright. They may be viewed, downloaded, or printed from this source but further reproduction or distribution in any format is prohibited without written permission. http://dspace.mit.edu/handle/1721.1/7582 353 pages application/pdf Massachusetts Institute of Technology |
| spellingShingle | Chemical Engineering. Mozdzierz, Nicholas J.(Nicholas Joseph) Developing scalable and modular technologies for continuous biopharmaceutical production |
| title | Developing scalable and modular technologies for continuous biopharmaceutical production |
| title_full | Developing scalable and modular technologies for continuous biopharmaceutical production |
| title_fullStr | Developing scalable and modular technologies for continuous biopharmaceutical production |
| title_full_unstemmed | Developing scalable and modular technologies for continuous biopharmaceutical production |
| title_short | Developing scalable and modular technologies for continuous biopharmaceutical production |
| title_sort | developing scalable and modular technologies for continuous biopharmaceutical production |
| topic | Chemical Engineering. |
| url | https://hdl.handle.net/1721.1/121817 |
| work_keys_str_mv | AT mozdzierznicholasjnicholasjoseph developingscalableandmodulartechnologiesforcontinuousbiopharmaceuticalproduction |